Abstract
A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 13-15 |
| Number of pages | 3 |
| Journal | Oncology |
| Volume | 12 |
| Issue number | 1 SUPPL.1 |
| Publication status | Published - 1998 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Paclitaxel plus doxorubicin in metastatic breast Ca : The Milan experience. / Gianni, Luca.
In: Oncology, Vol. 12, No. 1 SUPPL.1, 1998, p. 13-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Paclitaxel plus doxorubicin in metastatic breast Ca
T2 - The Milan experience
AU - Gianni, Luca
PY - 1998
Y1 - 1998
N2 - A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.
AB - A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0031892696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031892696&partnerID=8YFLogxK
M3 - Article
VL - 12
SP - 13
EP - 15
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 1 SUPPL.1
ER -